Advertisement

Photodynamic Therapy

  • Barbara KrammerEmail author
  • Thomas Verwanger
Chapter
Part of the Lecture Notes in Chemistry book series (LNC, volume 92)

Abstract

Photodynamic therapy (PDT) and fluorescence diagnosis (FD) are effective modalities for treatment or detection of tumors and various other diseases. Both are based on the same principle: accumulation of a photosensitizer (PS) in target cells (or tissue) and irradiation with visible light. Subsequently, the photo-activated PS either returns to the ground state by fluorescence (used for detection and diagnosis, FD) or crosses to its triplet state and reacts chemically with surrounding molecules. When molecular oxygen is present, reactive oxygen species (ROS) including singlet oxygen are generated, which oxidize, amongst others, proteins and lipids affecting the target and leading dose-dependently to its destruction (PDT). Since most PSs accumulate selectively in tumor tissue, PDT and FD are especially suited for tumor therapy or diagnosis, respectively. Although different kinds of tumors can be treated due to the unspecific action of ROS, PDT is mainly restricted to flat tumors located at inner or outer surfaces of the body as light accessibility has to be guaranteed. Various PSs such as porphyrins are approved or currently tested in clinical trials.

After administration to a patient, the PS is transported to the target and localizes in specific cell compartments. Following PS irradiation cells react in different ways to the oxidizing ROS. Low numbers of ROS can be quenched by antioxidants present in the cell and the damage be repaired. Even stimulation of proliferation or of immune reactions was observed. However, ROS levels above a specific threshold induce cell death mainly via apoptosis and necrosis.

Keywords

ROSReactive Oxygen Species Triplet State Singlet Oxygen ROSReactive Oxygen Species Concentration Singlet Oxygen Production 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, Hahn SM, Hamblin MR, Juzeniene A, Kessel D, Korbelik M, Moan J, Mroz P, Nowis D, Piette J, Wilson BC, Golab J (2011) Photodynamic therapy of cancer: an update. CA Cancer J Clin 61(4):250–281CrossRefGoogle Scholar
  2. 2.
    Agostinis P, Vantieghem A, Merlevede W, de Witte PA (2002) Hypericin in cancer treatment: more light on the way. Int J Biochem Cell Biol 34(3):221–241CrossRefGoogle Scholar
  3. 3.
    Allison RR, Downie GH, Cuenca R, Hu X-H, Childs CJ, Sibata CH (2004) Photosensitizers in clinical PDT. Photodiagn Photodyn Ther 1(1):27–42CrossRefGoogle Scholar
  4. 4.
    Anderson RR, Parrish JA (1981) The optics of human skin. J Invest Dermatol 77(1):13–19CrossRefGoogle Scholar
  5. 5.
    Bagdonas S, Ma LW, Iani V, Rotomskis R, Juzenas P, Moan J (2000) Phototransformations of 5-aminolevulinic acid-induced protoporphyrin IX in vitro: a spectroscopic study. Photochem Photobiol 72(2):186–192CrossRefGoogle Scholar
  6. 6.
    Ball DJ, Mayhew S, Wood SR, Griffiths J, Vernon DI, Brown SB (1999) A comparative study of the cellular uptake and photodynamic efficacy of three novel zinc phthalocyanines of differing charge. Photochem Photobiol 69(3):390–396CrossRefGoogle Scholar
  7. 7.
    Berg K, Madslien K, Bommer JC, Oftebro R, Winkelman JW, Moan J (1991) Light induced relocalization of sulfonated meso-tetraphenylporphines in NHIK 3025 cells and effects of dose fractionation. Photochem Photobiol 53(2):203–210CrossRefGoogle Scholar
  8. 8.
    Berg K, Western A, Bommer JC, Moan J (1990) Intracellular localization of sulfonated meso-tetraphenylporphines in a human carcinoma cell line. Photochem Photobiol 52(3):481–487CrossRefGoogle Scholar
  9. 9.
    Bergamini CM, Gambetti S, Dondi A, Cervellati C (2004) Oxygen, reactive oxygen species and tissue damage. Curr Pharm Des 10(14):1611–1626CrossRefGoogle Scholar
  10. 10.
    Berlanda J, Kiesslich T, Engelhardt V, Krammer B, Plaetzer K (2010) Comparative in vitro study on the characteristics of different photosensitizers employed in PDT. J Photochem Photobiol B 100(3):173–180CrossRefGoogle Scholar
  11. 11.
    Berlanda J, Kiesslich T, Oberdanner CB, Obermair FJ, Krammer B, Plaetzer K (2006) Characterization of apoptosis induced by photodynamic treatment with hypericin in A431 human epidermoid carcinoma cells. J Environ Pathol Toxicol Oncol 25(1–2):173–188CrossRefGoogle Scholar
  12. 12.
    Bonnett R, Martinez G (2001) Photobleaching of sensitizers used in photodynamic therapy. Tetrahedron 57:9513–9574CrossRefGoogle Scholar
  13. 13.
    Bonnett R, Martinez G (2002) Photobleaching of compounds of the 5,10,15,20-Tetrakis(m-hydroxyphenyl)porphyrin Series (m-THPP, m-THPC, and m-THPBC). Org Lett 4(12):2013–2016CrossRefGoogle Scholar
  14. 14.
    Brown SB, Brown EA, Walker I (2004) The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol 5(8):497–508CrossRefGoogle Scholar
  15. 15.
    Buytaert E, Dewaele M, Agostinis P (2007) Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Biochim Biophys Acta 1776(1):86–107Google Scholar
  16. 16.
    Castano AP, Demidova TN, Hamblin MR (2004) Mechanisms in photodynamic therapy: part one – photosensitizers, photochemistry and cellular localization. Photodiagn Photodyn Ther 1(4):279–293CrossRefGoogle Scholar
  17. 17.
    Castano AP, Mroz P, Hamblin MR (2006) Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer 6(7):535–545CrossRefGoogle Scholar
  18. 18.
    Charlesworth P, Truscott TG (1993) The use of 5-aminolevulinic acid (ALA) in photodynamic therapy (PDT). J Photochem Photobiol 18(1):99–100CrossRefGoogle Scholar
  19. 19.
    Chatterjee DK, Fong LS, Zhang Y (2008) Nanoparticles in photodynamic therapy: an emerging paradigm. Adv Drug Deliv Rev 60(15):1627–1637CrossRefGoogle Scholar
  20. 20.
    Chen WR, Huang Z, Korbelik M, Nordquist RE, Liu H (2006) Photoimmunotherapy for cancer treatment. J Environ Pathol Toxicol Oncol 25(1–2):281–291CrossRefGoogle Scholar
  21. 21.
    Coupienne I, Bontems S, Dewaele M, Rubio N, Habraken Y, Fulda S, Agostinis P, Piette J (2011) NF-kappaB inhibition improves the sensitivity of human glioblastoma cells to 5-aminolevulinic acid-based photodynamic therapy. Biochem Pharmacol 81(5):606–616CrossRefGoogle Scholar
  22. 22.
    Demidova TN, Hamblin MR (2004) Macrophage-targeted photodynamic therapy. Int J Immunopathol Pharmacol 17(2):117–126Google Scholar
  23. 23.
    Dolmans DE, Fukumura D, Jain RK (2003) Photodynamic therapy for cancer. Nat Rev Cancer 3(5):380–387CrossRefGoogle Scholar
  24. 24.
    Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q (1998) Photodynamic therapy. J Natl Cancer Inst 90(12):889–905CrossRefGoogle Scholar
  25. 25.
    Ericson MB, Grapengiesser S, Gudmundson F, Wennberg AM, Larko O, Moan J, Rosen A (2003) A spectroscopic study of the photobleaching of protoporphyrin IX in solution. Lasers Med Sci 18(1):56–62CrossRefGoogle Scholar
  26. 26.
    Feinweber D, Verwanger T, Bruggemann O, Teasdale I, Krammer B (2014) Applicability of new degradable hypericin-polymer-conjugates as photosensitizers: principal mode of action demonstrated by in vitro models. Photochem Photobiol Sci 13(11):1607–1620CrossRefGoogle Scholar
  27. 27.
    Firey PA, Rodgers MA (1987) Photo-properties of a silicon naphthalocyanine: a potential photosensitizer for photodynamic therapy. Photochem Photobiol 45(4):535–538CrossRefGoogle Scholar
  28. 28.
    Foote CS (1991) Definition of type I and type II photosensitized oxidation. Photochem Photobiol 54(5):659CrossRefGoogle Scholar
  29. 29.
    Garg AD, Dudek AM, Agostinis P (2013) Cancer immunogenicity, danger signals, and DAMPs: what, when, and how? Biofactors 39(4):355–367CrossRefGoogle Scholar
  30. 30.
    Gollnick SO, Vaughan L, Henderson BW (2002) Generation of effective antitumor vaccines using photodynamic therapy. Cancer Res 62(6):1604–1608Google Scholar
  31. 31.
    Gozuacik D, Kimchi A (2004) Autophagy as a cell death and tumor suppressor mechanism. Oncogene 23(16):2891–2906CrossRefGoogle Scholar
  32. 32.
    Halliwell B (1984) Oxygen radicals: a commonsense look at their nature and medical importance. Med Biol 62(2):71–77Google Scholar
  33. 33.
    Halliwell B, Gutteridge JM (1984) Role of iron in oxygen radical reactions. Methods Enzymol 105:47–56CrossRefGoogle Scholar
  34. 34.
    Hamblin MR (2008) Covalent photosensitizer conjugates part 2: peptides, polymers and small molecules for targeted photodynamic therapy. In: Hamblin MR, Mroz P (eds) Advances in photodynamic therapy: basic, translational and clinical. Artech House, NorwoodGoogle Scholar
  35. 35.
    Hamblin MR, Newman EL (1994) On the mechanism of the tumour-localising effect in photodynamic therapy. J Photochem Photobiol 23(1):3–8CrossRefGoogle Scholar
  36. 36.
    Henderson BW, Dougherty TJ (1992) How does photodynamic therapy work? Photochem Photobiol 55(1):145–157CrossRefGoogle Scholar
  37. 37.
    Huygens A, Crnolatac I, Develter J, Van Cleynenbreugel B, Van der Kwast T, de Witte PA (2008) Differential accumulation of hypericin in spheroids composed of T-24 transitional cell carcinoma cells expressing different levels of E-cadherin. J Urol 179(5):2014–2019CrossRefGoogle Scholar
  38. 38.
    Ito T (1978) Cellular and subcellular mechanisms of photodynamic action: the 1O2 hypothesis as a driving force in recent research. Photochem Photobiol 28(4–5):493–508CrossRefGoogle Scholar
  39. 39.
    Juzeniene A, Nielsen KP, Moan J (2006) Biophysical aspects of photodynamic therapy. J Environ Pathol Toxicol Oncol 25(1–2):7–28CrossRefGoogle Scholar
  40. 40.
    Kessel D (2002) Relocalization of cationic porphyrins during photodynamic therapy. Photochem Photobiol Sci 1(11):837–840CrossRefGoogle Scholar
  41. 41.
    Kiesslich T, Plaetzer K, Oberdanner CB, Berlanda J, Obermair FJ, Krammer B (2005) Differential effects of glucose deprivation on the cellular sensitivity towards photodynamic treatment-based production of reactive oxygen species and apoptosis-induction. FEBS Lett 579(1):185–190CrossRefGoogle Scholar
  42. 42.
    Klajnert B, Rozanek M, Bryszewska M (2012) Dendrimers in photodynamic therapy. Curr Med Chem 19(29):4903–4912CrossRefGoogle Scholar
  43. 43.
    Koch S (2015) In vitro tests of a new and improved hypericin-conjugate for application in photodynamic therapy and diagnosis. University of Salzburg, SalzburgGoogle Scholar
  44. 44.
    Kochevar IE (2004) Singlet oxygen signaling: from intimate to global. Sci STKE 2004(221):pe7Google Scholar
  45. 45.
    Konig K, Schneckenburger H, Ruck A, Steiner R (1993) In vivo photoproduct formation during PDT with ALA-induced endogenous porphyrins. J Photochem Photobiol 18(2–3):287–290CrossRefGoogle Scholar
  46. 46.
    Korbelik M (2011) Cancer vaccines generated by photodynamic therapy. Photochem Photobiol Sci 10(5):664–669CrossRefGoogle Scholar
  47. 47.
    Korbelik M, Merchant S (2012) Photodynamic therapy-generated cancer vaccine elicits acute phase and hormonal response in treated mice. Cancer Immunol Immunother 61(9):1387–1394CrossRefGoogle Scholar
  48. 48.
    Krammer B (2001) Vascular effects of photodynamic therapy. Anticancer Res 21(6B):4271–4277Google Scholar
  49. 49.
    Lucky SS, Soo KC, Zhang Y (2015) Nanoparticles in photodynamic therapy. Chem Rev 115(4):1990–2042CrossRefGoogle Scholar
  50. 50.
    Moan J (1986) Effect of bleaching of porphyrin sensitizers during photodynamic therapy. Cancer Lett 33(1):45–53CrossRefGoogle Scholar
  51. 51.
    Moan J (1990) On the difusion length of singlet oxygen in cells and tissues. J Photochem Photobiol 6:343–344CrossRefGoogle Scholar
  52. 52.
    Moan J, Berg K (1991) The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem Photobiol 53(4):549–553CrossRefGoogle Scholar
  53. 53.
    Moan J, Berg K, Anholt H, Madslien K (1994) Sulfonated aluminium phthalocyanines as sensitizers for photochemotherapy. Effects of small light doses on localization, dye fluorescence and photosensitivity in V79 cells. Int J Cancer 58(6):865–870CrossRefGoogle Scholar
  54. 54.
    Moan J, Streckyte G, Bagdonas S, Bech O, Berg K (1997) Photobleaching of protoporphyrin IX in cells incubated with 5-aminolevulinic acid. Int J Cancer 70(1):90–97CrossRefGoogle Scholar
  55. 55.
    Mroz P, Tegos GP, Gali H, Wharton T, Sarna T, Hamblin MR (2007) Photodynamic therapy with fullerenes. Photochem Photobiol Sci 6(11):1139–1149CrossRefGoogle Scholar
  56. 56.
    Muller P, Wilson BC (2014) Photodynamic therapy. In: Berstein M, Berger MS (eds) Neuro-oncology: the essentials, 3rd edn. Thieme, New YorkGoogle Scholar
  57. 57.
    Niedre M, Patterson MS, Wilson BC (2002) Direct near-infrared luminescence detection of singlet oxygen generated by photodynamic therapy in cells in vitro and tissues in vivo. Photochem Photobiol 75(4):382–391CrossRefGoogle Scholar
  58. 58.
    Niemz MH (2004) Laser-tissue interactions. Fundamentals and applications. Springer, BerlinGoogle Scholar
  59. 59.
    Ochsner M (1997) Photophysical and photobiological processes in the photodynamic therapy of tumours. J Photochem Photobiol 39(1):1–18CrossRefGoogle Scholar
  60. 60.
    Pazos MC, Nader HB (2007) Effect of photodynamic therapy on the extracellular matrix and associated components. Braz J Med Biol Res 40(8):1025–1035CrossRefGoogle Scholar
  61. 61.
    Pervaiz S, Olivo M (2006) Art and science of photodynamic therapy. Clin Exp Pharmacol Physiol 33(5–6):551–556CrossRefGoogle Scholar
  62. 62.
    Plaetzer K, Kiesslich T, Verwanger T, Krammer B (2003) The modes of cell death induced by PDT: an overview. Med Laser Appl 18(1):7–19CrossRefGoogle Scholar
  63. 63.
    Plaetzer K, Krammer B, Berlanda J, Berr F, Kiesslich T (2009) Photophysics and photochemistry of photodynamic therapy: fundamental aspects. Lasers Med Sci 24(2):259–268CrossRefGoogle Scholar
  64. 64.
    Prasad PN (2003) Introduction to biophotonics. Wiley, HobokenCrossRefGoogle Scholar
  65. 65.
    Preise D, Oren R, Glinert I, Kalchenko V, Jung S, Scherz A, Salomon Y (2009) Systemic antitumor protection by vascular-targeted photodynamic therapy involves cellular and humoral immunity. Cancer Immunol Immunother 58(1):71–84CrossRefGoogle Scholar
  66. 66.
    Preise D, Scherz A, Salomon Y (2011) Antitumor immunity promoted by vascular occluding therapy: lessons from vascular-targeted photodynamic therapy (VTP). Photochem Photobiol Sci 10(5):681–688CrossRefGoogle Scholar
  67. 67.
    Reddi E (1997) Role of delivery vehicles for photosensitizers in the photodynamic therapy of tumours. J Photochem Photobiol 37(3):189–195CrossRefGoogle Scholar
  68. 68.
    Reiners JJJ, Agostinis P, Berg K, Oleinick NL, Kessel D (2010) Assessing autophagy in the context of photodynamic therapy. Autophagy 6(1):7–18CrossRefGoogle Scholar
  69. 69.
    Ruck A, Beck G, Bachor R, Akgun N, Gschwend MH, Steiner R (1996) Dynamic fluorescence changes during photodynamic therapy in vivo and in vitro of hydrophilic A1(III) phthalocyanine tetrasulphonate and lipophilic Zn(II) phthalocyanine administered in liposomes. J Photochem Photobiol 36(2):127–133CrossRefGoogle Scholar
  70. 70.
    Ruhdorfer S, Sanovic R, Sander V, Krammer B, Verwanger T (2007) Gene expression profiling of the human carcinoma cell line A-431 after 5-aminolevulinic acid-based photodynamic treatment. Int J Oncol 30(5):1253–1262Google Scholar
  71. 71.
    Sanovic R, Krammer B, Grumboeck S, Verwanger T (2009) Time-resolved gene expression profiling of human squamous cell carcinoma cells during the apoptosis process induced by photodynamic treatment with hypericin. Int J Oncol 35(4):921–939Google Scholar
  72. 72.
    Sanovic R, Verwanger T, Hartl A, Krammer B (2011) Low dose hypericin-PDT induces complete tumor regression in BALB/c mice bearing CT26 colon carcinoma. Photodiagnosis Photodyn Ther 8(4):291–296CrossRefGoogle Scholar
  73. 73.
    Selbo PK, Hogset A, Prasmickaite L, Berg K (2002) Photochemical internalisation: a novel drug delivery system. Tumour Biol 23(2):103–112Google Scholar
  74. 74.
    Sharman WM, Allen CM, van Lier JE (2000) Role of activated oxygen species in photodynamic therapy. Methods Enzymol 319:376–400CrossRefGoogle Scholar
  75. 75.
    Sibata CH, Colussi VC, Oleinick NL, Kinsella TJ (2000) Photodynamic therapy: a new concept in medical treatment. Braz J Med Biol Res 33(8):869–880CrossRefGoogle Scholar
  76. 76.
    Svaasand LO (1984) Optical dosimetry for direct and interstitial photoradiation therapy of malignant tumors. Prog Clin Biol Res 170:91–114Google Scholar
  77. 77.
    Triesscheijn M, Baas P, Schellens JH, Stewart FA (2006) Photodynamic therapy in oncology. Oncologist 11(9):1034–1044CrossRefGoogle Scholar
  78. 78.
    Valenzeno DP (1987) Photomodification of biological membranes with emphasis on singlet oxygen mechanisms. Photochem Photobiol 46(1):147–160CrossRefGoogle Scholar
  79. 79.
    Valeur B (2001) Molecular fluorescence: principles and applications. Wiley-VCH, WeinheimCrossRefGoogle Scholar
  80. 80.
    van Dongen GA, Visser GW, Vrouenraets MB (2004) Photosensitizer-antibody conjugates for detection and therapy of cancer. Adv Drug Deliv Rev 56(1):31–52CrossRefGoogle Scholar
  81. 81.
    Wang HW, Zhu TC, Putt ME, Solonenko M, Metz J, Dimofte A, Miles J, Fraker DL, Glatstein E, Hahn SM, Yodh AG (2005) Broadband reflectance measurements of light penetration, blood oxygenation, hemoglobin concentration, and drug concentration in human intraperitoneal tissues before and after photodynamic therapy. J Biomed Opt 10(1):14004CrossRefGoogle Scholar
  82. 82.
    Weishaupt KR, Gomer CJ, Dougherty TJ (1976) Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumor. Cancer Res 36(7 PT 1):2326–2329Google Scholar
  83. 83.
    Wiegell SR, Stender IM, Na R, Wulf HC (2003) Pain associated with photodynamic therapy using 5-aminolevulinic acid or 5-aminolevulinic acid methylester on tape-stripped normal skin. Arch Dermatol 139(9):1173–1177CrossRefGoogle Scholar
  84. 84.
    Wilson BC, Jeeves WP, Lowe DM (1985) In vivo and post mortem measurements of the attenuation spectra of light in mammalian tissues. Photochem Photobiol 42(2):153–162CrossRefGoogle Scholar
  85. 85.
    Zancanela DC, Primo FL, Rosa AL, Ciancaglini P, Tedesco AC (2011) The effect of photosensitizer drugs and light stimulation on osteoblast growth. Photomed Laser Surg 29(10):699–705CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Department of Molecular BiologyUniversity of SalzburgSalzburgAustria

Personalised recommendations